Endocrinol Metab.  2022 Feb;37(1):74-83. 10.3803/EnM.2021.1293.

Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway

• Lee J
• Hong SW
• Kim MJ
• Moon SJ
• Kwon H
• Park SE
• Rhee EJ
• Lee WY

• KMID: 2527139
• DOI: http://doi.org/10.3803/EnM.2021.1293

Abstract

Background
Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to reduce body weight and liver fat content in patients with type 2 diabetes. Family with sequence similarity 3 member A (FAM3A) plays a vital role in regulating glucose and lipid metabolism. The aim of this study was to determine the mechanisms by which dulaglutide protects against hepatic steatosis in HepG2 cells treated with palmitic acid (PA).
Methods
HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM dulaglutide for 24 hours. Hepatic lipid accumulation was determined using Oil red O staining and triglyceride (TG) assay, and the expression of lipid metabolism-associated factor was analyzed using quantitative real time polymerase chain reaction and Western blotting.
Results
Dulaglutide significantly decreased hepatic lipid accumulation and reduced the expression of genes associated with lipid droplet binding proteins, de novo lipogenesis, and TG synthesis in PA-treated HepG2 cells. Dulaglutide also increased the expression of proteins associated with lipolysis and fatty acid oxidation and FAM3A in PA-treated cells. However, exendin-(9-39), a GLP-1R antagonist, reversed the expression of FAM3A, and fatty acid oxidation-associated factors increased due to dulaglutide. In addition, inhibition of FAM3A by siRNA attenuated the reducing effect of dulaglutide on TG content and its increasing effect on regulation of fatty acid oxidation.
Conclusion
These results suggest that dulaglutide could be used therapeutically for improving nonalcoholic fatty liver disease, and its effect could be mediated in part via upregulation of FAM3A expression through a GLP-1R-dependent pathway.

Keyword

Dulaglutide; Glucagon-like peptide-1 receptor; Non-alcoholic fatty liver disease; FAM3A; Fatty acid oxidation; HepG2 cells

Figure

• 

  Fig. 1 Dulaglutide (Dula) inhibits palmitic acid (PA)-induced lipid accumulation in HepG2 cells. Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid accumulation were evaluated using Oil red O staining (400× magnification) (A, B) and triglyceride (TG) content assay (C). mRNA and protein expression levels of perilipin 1 (PLIN1) and PLIN2 were analyzed using quantitative real time polymerase chain reaction and Western blotting, and were normalized to that of the 18S rRNA gene and β-actin, respectively (D, E). aP<0.05 and bP<0.01 compared with control (Con); cP<0.05 and dP<0.01 compared with PA-treated Con group.

• 

  Fig. 2 Dulaglutide (Dula) decreases lipogenesis and triglyceride (TG) synthesis and increases TG secretion in HepG2 cells treated with palmitic acid (PA). HepG2 cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. mRNA expression levels of the genes encoding sterol regulatory-binding protein 1 (SREBP-1), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) (A), diacylglycerol acyltransferase 1 (DGAT1), DGAT2 (B), microsomal triglyceride transfer protein (MTP), and apolipoprotein B (ApoB) (C) were analyzed using quantitative real time polymerase chain reaction and normalized to that of the 18S rRNA gene. aP<0.05 and bP<0.01 compared with control (Con); cP<0.05 and dP<0.01 compared with PA-treated Con group.

• 

  Fig. 3 Dulaglutide (Dula) increases lipolysis and fatty acid oxidation in HepG2 cells treated with palmitic acid (PA). HepG2 cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. (A, B, C, D, E, F) adipose triglyceride lipase (ATGL), phospho-hormone-sensitive lipase (p-HSL), sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting. aP<0.05 and bP<0.01 compared with control (Con); cP<0.05 and dP<0.01 compared with PA-treated Con group.

• 

  Fig. 4 Dulaglutide (Dula) increases the expression of family with sequence similarity 3 member A (FAM3A) via glucagon-like peptide-1 receptor (GLP-1R) in HepG2 cells treated with palmitic acid (PA). (A) HepG2 cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. (B) Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM dulaglutide and 100 nM exendin (9–39), a GLP-1R antagonist, for 24 hours. FAM3A, GLP-1R, sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting. aP<0.01 compared with control (Con); bP<0.05 compared with PA-treated Con group.

• 

  Fig. 5 Dulaglutide (Dula) inhibits lipid deposition and increases fatty acid oxidation via family with sequence similarity 3 member A (FAM3A). HepG2 cells transfected with 10 nM FAM3A small interfering RNA (siRNA) or control (Con) siRNA for 24 hours were pretreated with 400 μM palmitic acid (PA) for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. (A) Lipid deposition was evaluated using triglyceride (TG) content assay. (B) FAM3A, sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting. scr, scrambled siRNA. aP<0.05 and bP<0.01 compared with Con; cP<0.01 compared with PA-treated Con group; dP<0.01 compared with each non-transfected groups.

Reference

1. Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy. J Clin Med. 2019; 9:15.

2. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018; 18:245–50.

3. Jung I, Koo DJ, Lee MY, Moon SJ, Kwon H, Park SE, et al. Increased risk of nonalcoholic fatty liver disease in individuals with high weight variability. Endocrinol Metab (Seoul). 2021; 36:845–54.

4. Lee BW, Lee YH, Park CY, Rhee EJ, Lee WY, Kim NH, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J. 2020; 44:382–401.

5. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75:3313–27.

6. Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! Metabolism. 2019; 101:154001.

7. Rajeev SP, Wilding J. GLP-1 as a target for therapeutic intervention. Curr Opin Pharmacol. 2016; 31:44–9.

8. Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res. 2020; 9(F1000 Faculty Rev):239.

9. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5:262–9.

10. Gorriz JL, Soler MJ, Navarro-Gonzalez JF, Garcia-Carro C, Puchades MJ, D’Marco L, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020; 9:947.

11. Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2016; 18:1279–82.

12. Kajitani N, Takahashi J, Honda H, Hamahara J, Ando S. Severe visceral obesity, fatty liver and diabetes after orchiectomy for prostate cancer. Intern Med. 2020; 59:2281–5.

13. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017; 47:1206–11.

14. Zhu Y, Xu G, Patel A, McLaughlin MM, Silverman C, Knecht K, et al. Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics. 2002; 80:144–50.

15. Wang C, Chi Y, Li J, Miao Y, Li S, Su W, et al. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Hepatology. 2014; 59:1779–90.

16. Zhang X, Yang W, Wang J, Meng Y, Guan Y, Yang J. FAM3 gene family: a promising therapeutical target for NAFLD and type 2 diabetes. Metabolism. 2018; 81:71–82.

17. Yang J, Guan Y. Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2013; 28(Suppl 1):105–11.

18. Dasarathy S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology. 2014; 60:22–5.

19. Seebacher F, Zeigerer A, Kory N, Krahmer N. Hepatic lipid droplet homeostasis and fatty liver disease. Semin Cell Dev Biol. 2020; 108:72–81.

20. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res. 2008; 49:2283–301.

21. Wurie HR, Buckett L, Zammit VA. Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells. FEBS J. 2012; 279:3033–47.

22. Yu YH, Ginsberg HN. The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann Med. 2004; 36:252–61.

23. Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C. The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life. 2004; 56:379–85.

24. Carr RM, Dhir R, Mahadev K, Comerford M, Chalasani NP, Ahima RS. Perilipin staining distinguishes between steatosis and nonalcoholic steatohepatitis in adults and children. Clin Gastroenterol Hepatol. 2017; 15:145–7.

25. Tai ES, Ordovas JM. The role of perilipin in human obesity and insulin resistance. Curr Opin Lipidol. 2007; 18:152–6.

26. Gorucu Yilmaz S, Bozkurt H, Ndadza A, Thomford NE, Karaoglan M, Keskin M, et al. Childhood obesity risk in relationship to perilipin 1 (PLIN1) gene regulation by circulating microRNAs. OMICS. 2020; 24:43–50.

27. Libby AE, Bales E, Orlicky DJ, McManaman JL. Perilipin-2 deletion impairs hepatic lipid accumulation by interfering with sterol regulatory element-binding protein (SREBP) activation and altering the hepatic lipidome. J Biol Chem. 2016; 291:24231–46.

28. McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, Cain S, et al. Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res. 2013; 54:1346–59.

29. Carr RM, Peralta G, Yin X, Ahima RS. Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice. PLoS One. 2014; 9:e97118.

30. Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020; 63:2434–45.

31. Cusi K, Sattar N, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, et al. Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med. 2018; 35:1434–9.

32. Petit JM, Verges B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 2017; 43(Suppl 1):2S28–2S33.

33. Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017; 22:15–26.

34. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One. 2012; 7:e31394.

35. Yang W, Chi Y, Meng Y, Chen Z, Xiang R, Yan H, et al. FAM3A plays crucial roles in controlling PDX1 and insulin expressions in pancreatic beta cells. FASEB J. 2020; 34:3915–31.

36. Zhou Y, Jia S, Wang C, Chen Z, Chi Y, Li J, et al. FAM3A is a target gene of peroxisome proliferator-activated receptor gamma. Biochim Biophys Acta. 2013; 1830:4160–70.